“High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides

Zane, Cristina; Leali, C; Airò, Paolo; Panfilis, Giuseppe De; Calzavara‐Pinton, Piergiacomo

doi:10.1067/mjd.2001.110896

Cited by 84 publications

(69 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other diseases responding to UVA1 phototherapy include keloids [12], urticaria pigmentosa [13] and systemic lupus erythematosus [14]. The value of using UVA1 in the treatment of cutaneous lymphomas has also been qualified by several authors [15,16,17,18]. To our knowledge, this is the first report describing the successful use of UVA1 phototherapy in GSS.…”

Section: Introductionmentioning

confidence: 86%

Granulomatous Slack Skin Responds to UVA1 Phototherapy

et al. 2009

View full text Add to dashboard Cite

Granulomatous slack skin (GSS) is an extremely rare disorder within the group of cutaneous T cell lymphomas (CTCL). Ultraviolet A1 (UVA1) phototherapy has previously been reported to be useful in the treatment of CTCL such as mycosis fungoides. We report a 35-year-old Caucasian male with GSS treated with UVA1 phototherapy starting at 20 J/cm² UVA1 3 times a week and subsequently increased in increments of 5 J/cm² to a medium-range dose of 50 J/cm² per session. The patient underwent a total of 45 sessions with a cumulative dose of 1,495 J/cm² UVA1 without any adverse events. At the conclusion of UVA1 phototherapy, a decrease in erythema and skin thickness was observed which was most prominent in the periphery of the lesion in the right groin area. A follow-up 12 months after phototherapy showed continued treatment benefit. To our knowledge, this is the first report describing the successful use of UVA1 (340–400 nm) phototherapy in a patient with GSS.

show abstract

Section: Introductionmentioning

confidence: 86%

Granulomatous Slack Skin Responds to UVA1 Phototherapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…All volunteers were exposed to a geometric dose series of UV-A1 irradiation (7,10,14,20,28,40,56, and 80 J/cm 2 for those with skin types I and II, with an additional dose of 112 J/cm 2 , while omitting the lowest dose for those of skin types III and IV; 1.4 incremental factor) at 2 test sites (photoprotected lower back and inner forearm skin; 8ϫ1.5 cm 2 test areas).…”

Section: Irradiationmentioning

confidence: 99%

Dose-Response and Time-Course Characteristics of UV-A1 Erythema

Beattie

Dawe²,

Ferguson³

et al. 2005

Arch Dermatol

View full text Add to dashboard Cite

“…Ostatnie badania wskazują ponadto, że promieniowanie UVA1 hamuje aktywność kalcyneuryny in vivo i in vitro i wykorzystuje tę samą ścieżkę sygnałową w skórze co inhibitory kalcyneuryny. W leczeniu MF, niezależnie od fazy choroby, zaleca się codzienne dawki średnie 40-80 J/cm 2 oraz wysokie 80-130 J/cm 2 w ilości 10-35 na kurs [24][25][26]. Skuteczność światłoterapii PUVA lub UVA1 można zwiększyć, dodając retinoidy (acytretyna, izotretynoina), lub reksynoidy -beksaroten 300 mg/m 2 p.c.…”

Section: Chop -Cyclophosphamide + Hydroxydaunomycin (Doxorubicin) = Ounclassified

“…Recent studies have also demonstrated that UVA1 inhibits the activity of calcineurin in vivo and in vitro, and uses the same signalling pathway in the skin as calcineurin inhibitors. Regardless of the stage of MF, UVA1 treatment is administered in 10-35 sessions per course at medium or high daily doses (40-80 J/cm 2 and 80-130 J/cm 2 , respectively) [24][25][26]. The efficacy of PUVA or UVA1 phototherapy can be increased by combining it with retinoids (acitretin, isotretinoin), rexinoids -bexarotene at 300 mg/m 2 bosy surface area (BSA) p.o.…”

Section: Chop -Cyclophosphamide + Hydroxydaunomycin (Doxorubicin) = Omentioning

confidence: 99%

Primary cutaneous lymphomas – diagnostic and therapeutic guidelines of the Polish Dermatological Society

Sokołowska‐Wojdyło¹,

Maj²,

Robak³

et al. 2017

View full text Add to dashboard Cite

Primary cutaneous lymphomas are a group of rare lymphoproliferative diseases with incompletely understood pathogenesis. They comprise cutaneous T-cell lymphomas, cutaneous B-cell lymphomas and T/NKcell lymphomas. The aim of the guidelines is to provide physicians with a tool to facilitate the diagnostic and therapeutic process in patients with this group of diseases. The updated recommendations are consistent with the guidelines for haematologists and oncologists, which will enable the unification of diagnostics and therapy conducted by physicians of all specialties. However, it is important to note that therapeutic decisions must be made individually on the basis of the general condition of the patient, history of internal diseases and medicines used, with careful consideration of the potential efficacy and safety profile of the proposed treatment, which may differ from patient to patient. STRESZCZENIEChłoniaki pierwotnie skórne to grupa rzadkich rozrostów limfoproliferacyjnych o nie do końca poznanej patogenezie. Do grupy tej należą rozrosty T-komórkowe, B-komórkowe oraz z komórek T/NK. Celem niniejszych rekomendacji jest ułatwienie lekarzom procesu diagnostycznego i terapii pacjentów z tą grupą chorób. Uaktualnione zalecenia są zbieżne z rekomendacjami dla hematologów i onkologów, co pozwoli na ujednolicenie diagnostyki i terapii prowadzonych przez lekarzy wszystkich specjalności. Należy jednak pamiętać, że decyzje terapeutyczne lekarz musi podejmować indywidualnie, w zależności od stanu ogólnego pacjenta, obciążeń internistycznych, przyjmowanych leków, kierując się potencjalną skutecznością i profilem bezpieczeń-stwa, które mogą być różne u różnych pacjentów.

show abstract

“High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides

Cited by 84 publications

References 10 publications

Granulomatous Slack Skin Responds to UVA1 Phototherapy

Granulomatous Slack Skin Responds to UVA1 Phototherapy

Dose-Response and Time-Course Characteristics of UV-A1 Erythema

Primary cutaneous lymphomas – diagnostic and therapeutic guidelines of the Polish Dermatological Society

Contact Info

Product

Resources

About